Tyrosine kinase inhibitorFDA-approvedSecond-line
Regorafenib
How it works
Inhibits multiple kinases involved in tumor growth and angiogenesis, including VEGFR, PDGFR, and RAF.
Cancer types
Colorectal Cancer— All patients
Efficacy
Studies show that regorafenib can achieve response rates of around 1.4% in patients with metastatic colorectal cancer who have failed prior therapies.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing New Treatment for Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Testing Two Cancer Treatments in a Different Order | Colorectal Cancer | phase-2 | — | Source → |
| Testing a New Combination Treatment for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combination of Aramchol, Regorafenib, and Metformin Kills Tumor Cells | Melanoma | lab-study | — | Source → |
| Higher Doses of Regorafenib Linked to Improved Survival in Colorectal Cancer | Colorectal Cancer | observational | The median overall survival was 4.6 months for patients who received a cumulative dose of ≤4200 mg and 9.8 months for those who received >4200 mg. | Source → |
| New Combination Treatment Shows Promise for Rare Neuroendocrine Tumors | Pancreatic Cancer | phase-2 | The 6-month objective response rate was 18% (95% confidence interval: 8-31%), with a median progression-free survival of 5.5 months (95% CI: 3.6-8). | Source → |
| Stanniocalcin 1 May Help Predict Outcomes in Colorectal Cancer Patients | Colorectal Cancer | phase-3 | The median overall survival was 7.63 months in the STC1-low group and 3.81 months in the STC1-high group. | Source → |
| Combining cancer drugs shows moderate benefits for colorectal cancer patients | Colorectal Cancer | meta-analysis | The overall response rate was 6% and the median overall survival was 13.08 months. | Source → |
| Combining Chemotherapy and Radiation with Regorafenib in Rectal Cancer | Colorectal Cancer | phase-1 | Among the 19 patients who were treated at the recommended dose, 8 (42.1%) reached the primary endpoint, with 5 (26.3%) having near-complete regression and 3 (15.8%) complete regression. | Source → |
| Researchers Identify Potential Biomarker for Colorectal Cancer Treatment | Colorectal Cancer | phase-2 | — | Source → |
| Regorafenib Dosage May Vary by Body Weight in Colorectal Cancer Patients | Colorectal Cancer | observational | Among the light-weight patients, higher average dose was associated with shorter OS (IPTW adjusted HR=1.21, 95% CI 1.05 - 1.39) | Source → |
| Regorafenib Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | The median progression-free survival was 4 ± 0.2 months, and the median overall survival was 9 ± 1.2 months. | Source → |
| New Cancer Treatment Shows Promise in Early Human Trials | Colorectal Cancer | phase-1 | The overall response rate was 14.3% in phase 1a and 25.3% in phase 1b. | Source → |
| Real-World Comparison of Cancer Treatments Shows Similar Outcomes | Colorectal Cancer | observational | Median OS for the TAS-102 alone or prior regorafenib group was 6.66 months compared with 6.30 months for regorafenib alone or prior to TAS-102. | Source → |
| New Tool Helps Doctors Predict Which Colorectal Cancer Patients Will Benefit from Treatment | Colorectal Cancer | observational | Patients with a low-risk score survived 10.5 months after initiating regorafenib, while those with a high-risk score survived only 3.3 months. | Source → |
| Regorafenib Extends Survival in Metastatic Colorectal Cancer Patients | Colorectal Cancer | observational | The median overall survival was 12.0 months (95% CI: 9.7-14.3). | Source → |
| Regorafenib Treatment May Cause Colorectal Cancer Cells to Become Resistant | Colorectal Cancer | lab-study | — | Source → |
| Regorafenib Concentrations Linked to Survival in Colorectal Cancer Patients | Colorectal Cancer | phase-2 | Patients with a C2/C1 M-2 ratio ≥ median had improved survival compared to those < median (12.6 versus 4.0 months, P = 0.023), corresponding to a 66% mortality risk reduction in multivariate analysis. | Source → |
| Early Blood Test Predicts Effectiveness of Cancer Treatment | Colorectal Cancer | phase-2 | The early increase of Angiopoietin-2 was associated with a hazard ratio of 0.57 for progression-free survival and a trend towards longer overall survival. | Source → |
| Comparing Two Cancer Drugs in Real-World Patients | Colorectal Cancer | observational | No difference was observed for median time-to-treatment failure (regorafenib 2.7 months vs. fruquintinib 3.1 months, P = .200) or median overall survival (regorafenib 13.8 months vs. fruquintinib 11.3 months, P = .527). | Source → |
| New Biomarker for Colorectal Cancer Treatment Response Identified | Colorectal Cancer | phase-2 | Patients with baseline cfDNA > 26 ng·mL had shorter OS than those with cfDNA value below this threshold (4.0 vs 6.9 months; log-rank P = 0.0366). Patients with baseline mutant ctDNA > 2 ng·mL had shorter OS than those with mutant ctDNA below this threshold (log-rank P = 0.0154). | Source → |
| Trifluridine/Tipiracil Shows Promise for Metastatic Colorectal Cancer Patients | Colorectal Cancer | observational | The median overall survival was 12.4 months, and the median progression-free survival was 2.8 months. | Source → |
| New Compound Shows Promise in Treating Colorectal Cancer | Colorectal Cancer | lab-study | The compound was 14.5 times more potent than Regorafenib. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.